Short Report: omeprazole‐tetracycline combinations are inadequate as therapy for Helicobacter pylori infection

M. T. Al-Assi, R. M. Genta, D. Y. Graham

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Background: Current triple antimicrobial therapies cure Helicobacter pylori infection in 60–90% of cases but are cumbersome. Addition of omeprazole to amoxycillin has been shown to enhance effectiveness when compared to amoxycillin alone Method: We studied omeprazole 20 mg t.d.s. plus tetracycline 500 mg q.d.s. for 14 days (OMP/TCN) and omeprazole 40 mg in the morning plus tetracycline 500 mg q.d.s. along with bismuth subsalicylate tablets 2 q.d.s. (OMP/TCN/BSS) for 14 days. Forty‐four patients (19 OMP/TCN, 25 OMP/TCN/BSS) with H. pylori peptic ulcer disease were studied. H. pylori status was evaluated at least 4 weeks after ending antimicrobial therapy. Results: In the OMP/TCN group cure of H. pylori infection was achieved in 5/19 (26%). Adding bismuth to the regimen improved the results; 4 weeks after ending therapy cure of H. pylori infection was achieved in 12/25 (48%). Conclusions: Neither regimen can be recommended for routine cure of H. pylori infection. Although one cannot predict which antimicrobial therapies will be enhanced by the addition of omeprazole, these data suggest that future studies should evaluate drugs whose effectiveness is compromised by low pH.

Original languageEnglish (US)
Pages (from-to)259-262
Number of pages4
JournalAlimentary Pharmacology & Therapeutics
Volume8
Issue number2
DOIs
StatePublished - Apr 1994

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Short Report: omeprazole‐tetracycline combinations are inadequate as therapy for Helicobacter pylori infection'. Together they form a unique fingerprint.

Cite this